Next Phase Newsletter

A specialized investment firm is currently investing from its third oncology fund of USD 64 million. The firm generally makes investments in Series A, B or C equity rounds; the firm is not interested in seed rounds. The firm typically makes allocations of $3-8 million, and may either lead investments or act as a co-investor alongside a syndicate. The firm is open to oncology opportunities globally but has recently invested primarily in the USA.

The firm is currently focused on cancer therapeutics. The firm will consider any form of therapeutic molecule in oncology, including small molecules, antibodies or new technologies such as cell therapies. The firm generally invests at the late preclinical stage, from 6-12 months pre-IND, but is also interested in companies with Phase I or Phase II assets.

The firm places high importance on the management team’s scientific rigor and industry experience; the firm prefers to work with entrepreneurs who have led biotech companies previously. NThe firm also considers the strength of the investor syndicate and their alignment of interests.

If you are interested in more information about this investor and other investors tracked by LSN, please email mandates@lifesciencenation.com

A wholly owned venture arm subsidiary of a regional health insurance firm seeks to invest in technologies that are a strategic fit with members of the insurer’s network. The firm is flexible in terms of investment sizes and considers an array of capital structures including equity, convertible note, debt, and others. The firm typically co-invests with other investors but is open to leading a financing round. The firm is currently seeking new opportunities from across the US, while non-US opportunities may also be considered.

The firm is focused on opportunities in the following areas: Accountable Care Organizations, Consumer Solutions; Health Information Technology; and Behavioral Health. Potential examples may include consumer-facing patient engagement software, behavioral health technology, telemedicine, and B2B solutions that help healthcare organizations with decision making and financial planning. The firm is stage agnostic and would consider from pre-revenue to commercial-stage companies. Historically the firm has invested in patient monitoring system, EHR aggregation and analytics, and mobile health information platform.

The firm is seeking experienced, competent teams with disruptive innovations that are a strategic fit with its parent company’s network members. After investment, the firm typically requests a board seat or at least an observer position.

If you are interested in more information about this investor and other investors tracked by LSN, please email mandates@lifesciencenation.com

A US-based firm is investing from a multi-million dollar evergreen fund and is interested in a variety of sectors including the life science field. For life science investments, the firm typically allocates $2-15 million, and prefers to invest in Series B-C rounds. The firm invests primarily in the USA and Canada.

The firm is presently focused on technologies that involve an IT/software component, across digital health, healthcare services, medtech, and diagnostics. The firm is open to opportunities in any clinical indication, especially ocular. The firm is only interested in devices and diagnostics that have in-human data, have received marketing approval and are in the commercialization stage.

In the life science sector, the firm is not interested in early-stage R&D opportunities; howeverthe firm is open to both companies with an approved product on the market, and companies with a product in late-stage clinical trials. The firm takes the strength of the management team into consideration.

If you are interested in more information about this investor and other investors tracked by LSN, please email mandates@lifesciencenation.com

A private equity firm with offices across Asia and in the USA has over $4 billion AUM and is making new investments from three main funds. The firm has a dedicated life science investment team and invests in venture stage companies. The firm invests in various stages, typically start-up and early stage. For life science companies, the firm generally allocates USD 3-5 million per round. The firm is currently focused on opportunities in the US and Japan.

The firm invests opportunistically in the life sciences. The firm seeks to invest in innovative therapeutics, diagnostics, and medical devices. For therapeutics, the firm generally invests in novel platform technologies and considers both small molecules and biologics. The firm is indication agnostic and will consider orphan diseases. The firm is also agnostic to the stage of development, but typically invests in companies with a lead asset in clinical trials. For medical devices, the firm is also opportunistic and generally invests in devices that are in the clinic.

The firm is currently focused on private companies in the US and Japan. The firm generally requires a seat on the board of directors or observers.

If you are interested in more information about this investor and other investors tracked by LSN, please email mandates@lifesciencenation.com

A venture capital firm founded in 2014 with offices in Silicon Valley and Shanghai makes around half of its investments in mobile web development, and half in deep tech, including digital health, healthcare IT, and medical devices. The firm manages a $20 million fund, Fund 1, and is currently fundraising Fund 2. The firm typically invests an average of $300,000 per company, though this is dependent on the technology as the investment size may increase, particularly for hardware-based technology. The firm typically co-invests for Fund 1, and is anticipating leading investments with Fund 2.

The firm typically makes 12-20 new investments per year, and focuses on companies based in North America (USA & Canada), though is open to looking at companies based on a global-level. Furthermore, the firm has a considerable value-add in supporting companies that may be interested in moving their markets to Asia by passing potential deals to its Shanghai office as its source of deal flow, and making the right introductions to Asian investors and/or distribution partners.

The firm is open to all subsectors of digital health, healthcare IT, diagnostics, mobile app healthcare technologies, and all classes of medical devices. The firm is indication agnostic and looks primarily at early-stage companies, particularly at the seed pre-Series A stage.

The firm does not have a particular management team requirement, as it primarily assesses the technology itself. The firm will help the company fill the team if necessary. If leading the round, the firm will take a board seat after an investment.

If you are interested in more information about this investor and other investors tracked by LSN, please email mandates@lifesciencenation.com

A Private Equity company founded in 1982 and based in Boston, MA has raised 8 funds to date totaling approximately $1 billion in total assets raised. The firm is looking to invest $2-$15 million in preferred equity. The firm also considers in-license technologies and strategic acquisitions. For equity investments the firm prefers that companies are located in Eastern US and Midwest, but for acquisitions and in-licensing, the firm will consider companies located around the globe.

The firm is interested in companies in sectors of Therapeutics and Diagnostics, Medical Devices, Service Providers and Healthcare IT. The firm is generally open to all indications and sectors and has a strong preference for companies working with platform technologies. For equity investments, the firm looks for companies that have reached commercialization. For acquisitions and in-licensing, the firm will look at companies in Phase III of development or medical devices companies that are within one year of commercialization.

The firm is looking for experienced management teams with domain expertise and leadership skills that are capable of taking the company to the next value inflection point or additional capital raise. The firm is looking for companies that have at least $2-$30 million in yearly revenue. The firm is interested in company that are profitable or near break even and have demonstrated substantial opportunity for growth.

If you are interested in more information about this investor and other investors tracked by LSN, please email mandates@lifesciencenation.com

A $50 million strategic corporate venture capital fund formed by a pharmaceutical company headquartered in Japan seeks to make equity investment in startup companies that discover and develop innovative therapeutic products and/or drug-enabling platform technologies that demonstrate a clear potential to benefit cancer patients. Investment size can be flexible depending on the deal. The fund is currently seeking opportunities in the U.S., Europe and Japan.

The firm considers all modalities of oncology therapeutics with a special interest in biologics. The firm focuses on programs from drug discovery to preclinical development. The firm is looking for assets that have a strategic angle to its parent company’s pipeline.

The firm is looking for teams with strong sector expertise. The firm may request regional option or rights on a case-by-case basis.

If you are interested in more information about this investor and other investors tracked by LSN, please email mandates@lifesciencenation.com